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Introduction
Rhabdomyolysis is a clinical condition resulting from 
skeletal muscle damage due to traumatic or non-traumatic 
causes. The most common traumatic causes are natural 
disasters, traffic accidents and occupational accidents. 
By the same token the most common non-traumatic 
causes are medications, toxins, infections and electrolyte 
disorders. Statins, fibric acid derivatives, corticosteroids, 
colchicine, amphotericin B and many other drugs can 
cause rhabdomyolysis (1).
Case Presentation 
A 53-year-old male patient was admitted to the emergency 
department with a 3-day history of chest pain, abdominal 
pain and widespread body pain. The patient described 
pressure and compressive-type chest pain. He had a 
medical history of hypertension, coronary artery disease, 
hyperlipidemia (HL), and prior myocardial infarction. 
The patient used 40 mg atorvastatin for HL and a self-
initiated additional dose of atorvastatin 20 mg tablets 
without the advice of a physician. 
The patient’s vital signs were normal. Physical 
examination revealed tenderness to palpation of the 
entire body. Tenderness with palpation of the upper right 
quadrant was present during the abdominal examination. 
Electrocardiogram (ECG) demonstrated a normal sinus 
rhythm. The laboratory results were white blood cell 
(WBC): 13.49 μ/L, hemoglobin: 12.8 g/dL, CK-MB: 
17 IU/L, troponin I: 0.082 IU/L, blood urea nitrogen 
(BUN): 47.12 mg/dL, creatinine: 2.18 mg/dL, alanine 
transaminase (ALT): 1056.9 U/L, aspartate transaminase 
(AST): 2733.5 U/L, K: 5.73 mmol/L, creatinine kinase 
(CK): 351.000 U/L, lactate dehydrogenase (LDH): 4307 
U/L. Venous blood gas analysis showed pH: 7.29, pCO2: 
43.3 mm Hg and HCO3: 18.2, base deficit (BE): -4.6 
mmol/L. In the complete urinalysis; yellow color was seen 
and pH: 5, density: 1010, ketones (-), protein (-), glucose 
(-) and hemoglobin (++) and urine microscopy showed 14 
RBCs/HPF and 3 leukocytes/HPF.
The patient with chest pain and cardiac enzyme elevation 
was referred to the cardiology department and a pre-
diagnosis of acute coronary syndrome (ACS) was made. 
Serial ECG monitoring was in normal sinus rhythm. 
Bedside echocardiography was performed and no wall 
motion abnormality was detected. The patient was not 
thought to have ACS by the consultant cardiologist. There 
were no pathological findings on abdominal ultrasound. 
The patient was referred to internal medicine, and was 
diagnosed with rhabdomyolysis associated with the 
use of statin and was admitted to the internal medicine 
service. In the 24-hour urine analysis microalbumin 
and microprotein were measured at 21 and 143 mg/d 
respectively. Hepatitis and HIV serology were normal. 
Creatinine clearance by age was calculated as 44.34 mL/
min. The patient was considered at risk (R) stage according 
to the RIFLE (Risk, Injury, Failure, Loss of function, and 
End-stage renal disease) criteria and atorvastatin-induced 
rhabdomyolysis and ARF associated with rhabdomyolysis 
were diagnosed. Atorvastatin treatment was stopped. 
Adequate fluid replacement was administered. During 
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Abstract
Statins are commonly used drugs in the treatment of hyperlipidemia (HL), despite some 
undesirable side effects. These range from mild symptoms such as myopathy, muscle 
weakness and myalgia to severe muscle weakness associated with chronic myopathy 
and acute renal failure (ARF) as a result of rhabdomyolysis. The most serious and deadly 
side effect of statins is rhabdomyolysis. The case presented here is of a patient with 
rhabdomyolysis due to treatment with the antihyperlipidemic drug, atorvastatin.
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hospitalization, the need for hemodialysis arose and 
dialysis was applied 4 times. The follow-up laboratory 
test results were BUN: 31 mg/dL, serum creatinine: 1.2 
mg/dL, AST: 19 U/L, ALT: 38 U/L, CK: 284 U/L, Na: 141 
mmol/L, K 3.4 mmol/L, P 3.4 mg/dL. Polyuria developed 
but decreased during the follow-up and renal function 
tests returned to normal levels. When an improvement 
was determined in the general symptoms and laboratory 
findings, the patient was discharged with a treatment plan 
and an outpatient clinic follow-up examination for 10 
days later. 
Discussion
Statins are widely used in the treatment of HL and they 
are usually safe drugs. However, findings ranging from 
non-specific symptoms such as myalgia and muscle 
weakness to rhabdomyolysis-induced ARF can be seen 
in patients taking statins. This situation is associated 
with elevation of CK. Clinical symptoms and serum CK 
levels improve quickly after discontinuation of the drug. 
The risk of developing statin-associated myalgia has been 
reported as 2%-11%, risk of myositis at 0.5%, and the risk 
of rhabdomyolysis at approximately 0.1% (2).
Rhabdomyolysis is defined as a severe myopathy with 
muscle symptoms and elevation of CK more than ten 
times the upper limit of normal (3). Clinical signs of 
rhabdomyolysis include pain in the muscles, tenderness, 
skin discoloration in the affected regions, pain mostly 
in the waist and thigh, fatigue, tachycardia, nausea and 
vomiting, fever, and palpitations (4). The most common 
presentation of rhabdomyolysis is muscle weakness, pain, 
cramps and edema with tea colored (red-brown) urine 
(5). ARF occurs in approximately 30% of rhabdomyolysis 
cases. Rhabdomyolysis is the cause in 8% of all cases 
of ARF. Rhabdomyolysis-induced ARF is caused by 
hypovolemia related to rhabdomyolysis or the direct toxic 
effect of myoglobin if there is no underlying cause (6).
In the current case, the patient had been taking additional 
treatment without medical advice and statin-induced 
rhabdomyolysis and ARF developed. 
In conclusion, statins are in current widespread use 
and because of the potential fatal side effects, these 
medications should be chosen carefully. These drugs must 
be used for the correct indications and at the right dose 
and there should be regular monitoring of kidney and 
liver functions and muscle enzymes. Patients must be 
evaluated for rhabdomyolysis facilitating factors, and they 
should be informed about the side effects and symptoms 
of myopathy.
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